What you should know about the new Alzheimer’s drug

An older man rests his chin on his cane while sitting down at a table

In a highly anticipated announcement, the US Food and Drug Administration last week approved the first new drug for Alzheimer’s disease in nearly two decades.

That approval was not without controversy. Both before and after the FDA’s decision, physicians and researchers expressed a wide variety of perspectives on the drug’s potential, given a limited evidence base, and multiple stops and starts in its development and approval process.

The Alzheimer’s drug, called aducanumab during development and clinical trials, will be branded and sold as Aduhelm.

“I really believe this kicks off a new era in the fight against Alzheimer’s disease,” says Stephen Salloway, professor of neurology and psychiatry at Brown University who has been closely involved with the drug’s clinical development since the beginning.

Salloway directs the Memory and Aging Program at Butler Hospital and has been researching Alzheimer’s disease for 30 years.


 Get The Latest By Email

Weekly Magazine Daily Inspiration

He was a site principal investigator at Butler for both Phase 1 and Phase 3 trials of aducanumab, co-chair of the investigative steering committee for the Phase 3 program, and has advised the drug’s manufacturer, Biogen, on safety protocols and side effect management.

Here, he explains the key takeaways from the FDA’s headline-making decision and what it means for Alzheimer’s patients and for future research of the disease:

About The Author

Corrie Pikul-Brown

books_health

This article originally appeared on Futurity

AVAILABLE LANGUAGES

English Afrikaans Arabic Chinese (Simplified) Chinese (Traditional) Danish Dutch Filipino Finnish French German Greek Hebrew Hindi Hungarian Indonesian Italian Japanese Korean Malay Norwegian Persian Polish Portuguese Romanian Russian Spanish Swahili Swedish Thai Turkish Ukrainian Urdu Vietnamese

follow InnerSelf on

facebook icontwitter iconyoutube iconinstagram iconpintrest iconrss icon

 Get The Latest By Email

Weekly Magazine Daily Inspiration

Tuesday, 25 July 2023 16:09

Volunteering in late life may be more than just a noble act of giving back to the community; it could be a critical factor in safeguarding the brain against cognitive decline and dementia.

Wednesday, 12 May 2021 08:30

In 2019, Burger King Sweden released a plant-based burger, the Rebel Whopper, and the reaction was underwhelming. So, the company challenged its customers to taste the difference.

Wednesday, 21 April 2021 07:23

Whether it’s your arthritic relative who knows rain is on the way when their knees ache or your lifelong pal who gets a headache when a storm is approaching, we all know somebody who claims they...

Thursday, 06 May 2021 00:51

Have you ever walked into an empty room and immediately sensed that the atmosphere was laced with tension? You may have had no idea what occurred there prior to your arrival, yet you somehow knew...

Thursday, 15 April 2021 07:13

As a species, humans are wired to collaborate. That’s why lockdowns and remote work have felt difficult for many of us during the COVID-19 pandemic.

Tuesday, 04 May 2021 08:32

Cognitive motor training helps in the fight against Alzheimer’s and dementia, according to new research.

New Attitudes - New Possibilities

InnerSelf.comClimateImpactNews.com | InnerPower.net
MightyNatural.com | WholisticPolitics.com | InnerSelf Market
Copyright ©1985 - 2021 InnerSelf Publications. All Rights Reserved.